Colorectal cancer therapeutics are drugs used for treatment of colorectal cancer or bowel cancer, which affects large intestine or rectum. The therapeutics includes targeted drug therapies, immunotherapy drugs and chemotherapy. Targeted drug therapies are more effective with minimal side effects as compared to conventional chemotherapy treatments. The targeted therapies block abnormal signals that cause cancer growth and spread and help in slowing or stopping growth of cancer cells.

Colorectal cancer therapeutics market is estimated to be valued at USD 8.98 Bn in 2024 and is expected to reach USD 12.10 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 4.3% from 2024 to 2031.

Key Takeaways

Key players operating in the Colorectal Cancer Therapeutics are Sanofi, Bristol-Myers Squibb Company, Bayer AG, Ono Pharmaceutical Co. Ltd, ALX Oncology Inc., Daiichi Sankyo Company, Limited, Pfizer Inc., Exelixis, Inc., SOTIO Biotech AG, AB Science, BioNTech SE, Effector Therapeutics, Inc., and Treos Bio Limited. Growing incidences and increasing risk factors associated with colorectal cancer are driving the demand of colorectal cancer therapeutics globally. Major players are focusing on development of novel combination therapies and targeted drug therapies to expand their global presence.

Market Key Trends

One of the key trends witnessed in the colorectal cancer therapeutics market is increasing focus on development of combination therapies. Combination therapy involves administration of two or more drugs aimed at counteracting resistance of cancer cells to individual drugs. Ongoing clinical trials evaluating targeted drug combinations are offering promising results in overcoming resistance.

For instance, combination of Avastin with chemotherapeutic agents has shown improved progression free survival rates. Rising number of product approvals for combination therapies is expected to drive the Colorectal Cancer Therapeutics Market Demand during forecast period.

Porter’s Analysis

Threat of new entrants: Low development and commercialization costs act as a barrier.

Bargaining power of buyers: Large pharmaceutical companies have significant influence on pricing.

Bargaining power of suppliers: Established suppliers have specialized inputs and collaboration is important.

Threat of new substitutes: Alternative treatment options present competitive pressures.

Competitive rivalry: Colorectal Cancer Therapeutics Companies compete on clinical trial results, patented drugs and targeted therapies.

Geographical Regions

North America currently holds the largest share of the colorectal cancer therapeutics market owing to high diagnosis and treatment rates. The availability of advanced healthcare facilities and reimbursement for colorectal cancer treatment in the region contribute to its dominance.

Asia Pacific is poised to be the fastest growing regional market over the forecast period. This is attributed to rising healthcare expenditure, growing cancer awareness programs, increasing demand for modern therapies and expansion of private healthcare sectors in developing APAC countries.

Discover the Report for More Insights, Tailored to Your Language.

French German Italian Russian Japanese Chinese Korean Portuguese

Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemical and materials, defense and aerospace, consumer goods, etc. (https://www.linkedin.com/in/money-singh-590844163)